Evaluation of cytokine modulators for asthma (Q35674146)

9 August 2017

1 reference

title

Evaluation of cytokine modulators for asthma (English)

1 reference

9 August 2017

1 reference

Leslie Hendeles

1

1 reference

9 August 2017

Michael Asmus

series ordinal

2

1 reference

9 August 2017

Sarah Chesrown

series ordinal

3

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Paediatric Respiratory Reviews

9 August 2017

published in

1 reference

9 August 2017

volume

5 Suppl A

1 reference

9 August 2017

page(s)

S107-12

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

9 August 2017

1 reference

7 January 2021

Cytokine-directed therapies for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Allergy and allergic diseases. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Airway remodeling in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Theophylline. A review of its potential steroid sparing effects in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

The trials and tribulations of IL-5, eosinophils, and allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

A new element in the mechanism of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

New clues to asthma therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

A TH2 cytokine inhibitor for airway inflammation in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990020-6

7 January 2021

10.1016/S1526-0542(04)90020-6

Identifiers

DOI

1 reference

9 August 2017

1 reference